Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1651)	3/1/2007 12:25:08 PM
From: software salesperson	Read Replies (1) \| Respond to of 2240

From yesterday's conf. call, I was primarily listening for 010 updates: 1) 010 monotherapy for 2nd line metastatic melanoma- - started 3/06; completed enrollment 12/06; 150 patients; top line data and BLA 2nd 1/2 2007; endpoint: best objective response rate; other supportive studies are fully enrolled; fda has approved monotherapy products in 2nd and 3rd line with 9% objective response rate 2) 010 +DTIC vs. DTIC in 1st line metastatic melanoma - - endpoint is PFS; announced 6/96; expected enrollment: mid 2008; BLA late 2008- early 2009; 500 patients 3) vaccine combination : ( 010 vs. 1379(vaccine) vs. 010+ 1379 ??) - - expected enrollment: late 2008 thus, 2 very long delays. sales